1
|
Gabai A, Zeppieri M, Finocchio L, Salati C. Innovative Strategies for Drug Delivery to the Ocular Posterior Segment. Pharmaceutics 2023; 15:1862. [PMID: 37514050 PMCID: PMC10385847 DOI: 10.3390/pharmaceutics15071862] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/17/2023] Open
Abstract
Innovative and new drug delivery systems (DDSs) have recently been developed to vehicle treatments and drugs to the ocular posterior segment and the retina. New formulations and technological developments, such as nanotechnology, novel matrices, and non-traditional treatment strategies, open new perspectives in this field. The aim of this mini-review is to highlight promising strategies reported in the current literature based on innovative routes to overcome the anatomical and physiological barriers of the vitreoretinal structures. The paper also describes the challenges in finding appropriate and pertinent treatments that provide safety and efficacy and the problems related to patient compliance, acceptability, effectiveness, and sustained drug delivery. The clinical application of these experimental approaches can help pave the way for standardizing the use of DDSs in developing enhanced treatment strategies and personalized therapeutic options for ocular pathologies.
Collapse
Affiliation(s)
- Andrea Gabai
- Department of Ophthalmology, University Hospital of Udine, 33100 Udine, Italy
| | - Marco Zeppieri
- Department of Ophthalmology, University Hospital of Udine, 33100 Udine, Italy
| | - Lucia Finocchio
- Department of Ophthalmology, University Hospital of Udine, 33100 Udine, Italy
- Department of Ophthalmology, Nuovo Ospedale Santo Stefano, 59100 Prato, Italy
| | - Carlo Salati
- Department of Ophthalmology, University Hospital of Udine, 33100 Udine, Italy
| |
Collapse
|
2
|
Ghanavi M, Khoshandam A, Aslzad S, Fathi M, Barzegari A, Dalir Abdolahinia E, Adibkia K, Barar J, Omidi Y. Injectable thermosensitive PEG-g-chitosan hydrogel for ocular delivery of vancomycin and prednisolone. J Drug Deliv Sci Technol 2023. [DOI: 10.1016/j.jddst.2023.104385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/28/2023]
|
3
|
Thacker M, Singh V, Basu S, Singh S. Biomaterials for dry eye disease treatment: Current overview and future perspectives. Exp Eye Res 2023; 226:109339. [PMID: 36470431 DOI: 10.1016/j.exer.2022.109339] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Revised: 11/04/2022] [Accepted: 11/27/2022] [Indexed: 12/09/2022]
Abstract
Dry eye disease (DED) is an emerging health problem affecting millions of individuals every year. The current treatments for DED include lubricating eye drops and anti-inflammatory agents. These agents have to be used frequently and contain preservatives, which can damage the ocular surface. A substantially long-acting treatment with better bioavailability on the ocular surface might reduce the frequency of drug use and its side effects. This review summarizes the current state of different biomaterials-nanosystems, hydrogels, and contact lenses used as drug delivery systems in DED. The explored drugs in biomaterial formulation are cyclosporin, ocular lubricants, and topical steroids. Most of the data is from animal models where increased drug delivery and desired therapeutic effects could be obtained; however, trials involving human participants are yet to happen. There is no published study comparing the different types of biomaterials for DED use. Long-term studies evaluating their ocular toxicity and biocompatibility would enhance their transition to human use. Overall they look promising for DED treatment, but they are still in the stage of technological advancement and clinical studies.
Collapse
Affiliation(s)
- Minal Thacker
- Brien Holden Center for Eye Research (BHERC), L V Prasad Eye Institute, Hyderabad, 500034, Telangana, India; Centre for Ocular Regeneration, L V Prasad Eye Institute, Hyderabad, 500034, Telangana, India
| | - Vivek Singh
- Brien Holden Center for Eye Research (BHERC), L V Prasad Eye Institute, Hyderabad, 500034, Telangana, India; Centre for Ocular Regeneration, L V Prasad Eye Institute, Hyderabad, 500034, Telangana, India
| | - Sayan Basu
- Brien Holden Center for Eye Research (BHERC), L V Prasad Eye Institute, Hyderabad, 500034, Telangana, India; The Cornea Institute, L V Prasad Eye Institute, Hyderabad, 500034, Telangana, India
| | - Swati Singh
- Centre for Ocular Regeneration, L V Prasad Eye Institute, Hyderabad, 500034, Telangana, India; Ophthalmic Plastic Surgery Services, L V Prasad Eye Institute, Hyderabad, 500034, Telangana, India.
| |
Collapse
|
4
|
Das B, Nayak AK, Mallick S. Lipid-based nanocarriers for ocular drug delivery: An updated review. J Drug Deliv Sci Technol 2022. [DOI: 10.1016/j.jddst.2022.103780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
5
|
Jafari Z, Bigham A, Sadeghi S, Dehdashti SM, Rabiee N, Abedivash A, Bagherzadeh M, Nasseri B, Karimi-Maleh H, Sharifi E, Varma RS, Makvandi P. Nanotechnology-Abetted Astaxanthin Formulations in Multimodel Therapeutic and Biomedical Applications. J Med Chem 2022; 65:2-36. [PMID: 34919379 PMCID: PMC8762669 DOI: 10.1021/acs.jmedchem.1c01144] [Citation(s) in RCA: 23] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2021] [Indexed: 12/13/2022]
Abstract
Astaxanthin (AXT) is one of the most important fat-soluble carotenoids that have abundant and diverse therapeutic applications namely in liver disease, cardiovascular disease, cancer treatment, protection of the nervous system, protection of the skin and eyes against UV radiation, and boosting the immune system. However, due to its intrinsic reactivity, it is chemically unstable, and therefore, the design and production processes for this compound need to be precisely formulated. Nanoencapsulation is widely applied to protect AXT against degradation during digestion and storage, thus improving its physicochemical properties and therapeutic effects. Nanocarriers are delivery systems with many advantages─ease of surface modification, biocompatibility, and targeted drug delivery and release. This review discusses the technological advancement in nanocarriers for the delivery of AXT through the brain, eyes, and skin, with emphasis on the benefits, limitations, and efficiency in practice.
Collapse
Affiliation(s)
- Zohreh Jafari
- Department
of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, 19857-17443 Tehran, Iran
| | - Ashkan Bigham
- Institute
of Polymers, Composites and Biomaterials
- National Research Council (IPCB-CNR), Viale J.F. Kennedy 54 - Mostra D’Oltremare
pad. 20, 80125 Naples, Italy
| | - Sahar Sadeghi
- Department
of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, 19857-17443 Tehran, Iran
| | - Sayed Mehdi Dehdashti
- Cellular
and Molecular Biology Research Center, Shahid
Beheshti University of Medical Sciences, 19857-17443 Tehran, Iran
| | - Navid Rabiee
- Department
of Chemistry, Sharif University of Technology, 11155-9161 Tehran, Iran
- Department
of Physics, Sharif University of Technology, 11155-9161 Tehran, Iran
- School
of Engineering, Macquarie University, Sydney, New South Wales 2109, Australia
| | - Alireza Abedivash
- Department
of Basic Sciences, Sari Agricultural Sciences
and Natural Resources University, 48181-68984 Sari, Iran
| | - Mojtaba Bagherzadeh
- Department
of Chemistry, Sharif University of Technology, 11155-9161 Tehran, Iran
| | - Behzad Nasseri
- Department
of Medical Biotechnology, Faculty of Advance Medical Sciences, Tabriz University of Medical Sciences, 51664 Tabriz, Iran
| | - Hassan Karimi-Maleh
- School
of Resources and Environment, University
of Electronic Science and Technology of China, P.O. Box 611731, Xiyuan Avenue, 610054 Chengdu, PR China
- Department
of Chemical Engineering, Laboratory of Nanotechnology,
Quchan University of Technology, 94771-67335 Quchan, Iran
- Department
of Chemical Sciences, University of Johannesburg, P.O. Box 17011, Doornfontein Campus,
2028, 2006 Johannesburg, South Africa
| | - Esmaeel Sharifi
- Institute
of Polymers, Composites and Biomaterials
- National Research Council (IPCB-CNR), Viale J.F. Kennedy 54 - Mostra D’Oltremare
pad. 20, 80125 Naples, Italy
- Department
of Tissue Engineering and Biomaterials, School of Advanced Medical
Sciences and Technologies, Hamadan University
of Medical Sciences, 6517838736 Hamadan, Iran
| | - Rajender S. Varma
- Regional
Centre of Advanced Technologies and Materials, Czech Advanced Technology
and Research Institute, Palacky University, Šlechtitelů 27, 78371 Olomouc, Czech Republic
| | - Pooyan Makvandi
- Centre for
Materials Interfaces, Istituto Italiano
di Tecnologia, viale
Rinaldo Piaggio 34, 56025 Pontedera, Pisa, Italy
| |
Collapse
|
6
|
du Toit LC, Choonara YE, Pillay V. An Injectable Nano-Enabled Thermogel to Attain Controlled Delivery of p11 Peptide for the Potential Treatment of Ocular Angiogenic Disorders of the Posterior Segment. Pharmaceutics 2021; 13:pharmaceutics13020176. [PMID: 33525495 PMCID: PMC7910951 DOI: 10.3390/pharmaceutics13020176] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2020] [Revised: 01/18/2021] [Accepted: 01/20/2021] [Indexed: 11/16/2022] Open
Abstract
This investigation focused on the design of an injectable nano-enabled thermogel (nano-thermogel) system to attain controlled delivery of p11 anti-angiogenic peptide for proposed effective prevention of neovascularisation and to overcome the drawbacks of the existing treatment approaches for ocular disorders characterised by angiogenesis, which employ multiple intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) antibodies. Synthesis of a polyethylene glycol-polycaprolactone-polyethylene glycol (PEG-PCL-PEG) triblock co-polymer was undertaken, followed by characterisation employing Fourier-transform infrared (FTIR) spectroscopy, nuclear magnetic resonance (NMR) spectroscopy and differential scanning calorimetry (DSC) to ascertain the chemical stability and integrity of the co-polymer instituted for nano-thermogel formulation. The p11 anti-angiogenic peptide underwent encapsulation within poly(lactic-co-glycolic acid) (PLGA) nanoparticles via a double emulsion solvent evaporation method and was incorporated into the thermogel following characterisation by scanning electron microscopy (SEM), zeta size and zeta-potential analysis. The tube inversion approach and rheological analysis were employed to ascertain the thermo-sensitive sol-gel conversion of the nano-thermogel system. Chromatographic assessment of the in vitro release of the peptide was performed, with stability confirmation via Tris-Tricine PAGE (Polyacrylamide Gel Electrophoresis). In vitro biocompatibility of the nano-thermogel system was investigated employing a retinal cell line (ARP-19). A nanoparticle size range of 100–200 nm and peptide loading efficiency of 67% was achieved. Sol-gel conversion of the nano-thermogel was observed between 32–45 °C. Release of the peptide in vitro was sustained, with maintenance of stability, for 60 days. Biocompatibility assessment highlighted 97–99% cell viability with non-haemolytic ability, which supports the potential applicability of the nano-thermogel system for extended delivery of peptide for ocular disorder treatment.
Collapse
Affiliation(s)
| | - Yahya Essop Choonara
- Correspondence: ; Tel.: +27-11-717-2052; Fax: +27-11-642-4355 or +27-86-553-4733
| | | |
Collapse
|
7
|
Khiev D, Mohamed ZA, Vichare R, Paulson R, Bhatia S, Mohapatra S, Lobo GP, Valapala M, Kerur N, Passaglia CL, Mohapatra SS, Biswal MR. Emerging Nano-Formulations and Nanomedicines Applications for Ocular Drug Delivery. NANOMATERIALS 2021; 11:nano11010173. [PMID: 33445545 PMCID: PMC7828028 DOI: 10.3390/nano11010173] [Citation(s) in RCA: 69] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Revised: 01/06/2021] [Accepted: 01/07/2021] [Indexed: 12/11/2022]
Abstract
Ocular diseases can deteriorate vision to the point of blindness and thus can have a major impact on the daily life of an individual. Conventional therapies are unable to provide absolute therapy for all ocular diseases due to the several limitations during drug delivery across the blood-retinal barrier, making it a major clinical challenge. With recent developments, the vast number of publications undergird the need for nanotechnology-based drug delivery systems in treating ocular diseases. The tool of nanotechnology provides several essential advantages, including sustained drug release and specific tissue targeting. Additionally, comprehensive in vitro and in vivo studies have suggested a better uptake of nanoparticles across ocular barriers. Nanoparticles can overcome the blood-retinal barrier and consequently increase ocular penetration and improve the bioavailability of the drug. In this review, we aim to summarize the development of organic and inorganic nanoparticles for ophthalmic applications. We highlight the potential nanoformulations in clinical trials as well as the products that have become a commercial reality.
Collapse
Affiliation(s)
- Dawin Khiev
- MSPN Graduate Programs, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA; (D.K.); (Z.A.M.); (R.V.); (S.S.M.)
| | - Zeinab A. Mohamed
- MSPN Graduate Programs, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA; (D.K.); (Z.A.M.); (R.V.); (S.S.M.)
| | - Riddhi Vichare
- MSPN Graduate Programs, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA; (D.K.); (Z.A.M.); (R.V.); (S.S.M.)
| | - Ryan Paulson
- Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA; (R.P.); (S.B.)
| | - Sofia Bhatia
- Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA; (R.P.); (S.B.)
| | - Subhra Mohapatra
- Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA;
- James A. Haley Veterans’ Hospital, Tampa, FL 33612, USA
| | - Glenn P. Lobo
- Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA;
| | - Mallika Valapala
- School of Optometry, Indiana University, Bloomington, IN 47401, USA;
| | - Nagaraj Kerur
- Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA;
| | | | - Shyam S. Mohapatra
- MSPN Graduate Programs, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA; (D.K.); (Z.A.M.); (R.V.); (S.S.M.)
- James A. Haley Veterans’ Hospital, Tampa, FL 33612, USA
- Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
| | - Manas R. Biswal
- MSPN Graduate Programs, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA; (D.K.); (Z.A.M.); (R.V.); (S.S.M.)
- Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA; (R.P.); (S.B.)
- Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
- Department of Ophthalmology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
- Correspondence: ; Tel.: +1-813-974-8333
| |
Collapse
|
8
|
Ocular prodrugs: Attributes and challenges. Asian J Pharm Sci 2020; 16:175-191. [PMID: 33995612 PMCID: PMC8105420 DOI: 10.1016/j.ajps.2020.08.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Revised: 08/17/2020] [Accepted: 08/26/2020] [Indexed: 11/23/2022] Open
Abstract
Ocular drug delivery is one of the most attention-grabbing and challenging endeavors among the numerous existing drug delivery systems. From a drug delivery point of view, eye is an intricate organ to investigate and explore. In spite of many limitations, advancements have been made with the intention of improving the residence time or permeation of the drug in the ocular region. Poor bioavailability of topically administered drugs is the major issue pertaining to ocular drug delivery. Several efforts have been made towards improving precorneal residence time and corneal penetration, e.g. iontophoresis, prodrugs and ion-pairing, etc. Prodrug approach (chemical approach) has been explored by the formulation scientists to optimize the physicochemical and biochemical properties of drug molecules for improving ocular bioavailability. Formulation of ocular prodrugs is a challenging task as they should exhibit optimum chemical stability as well as enzymatic liability so that they are converted into parent drug after administration at the desired pace. This review will encompass the concept of derivatization and recent academic and industrial advancements in the field of ocular prodrugs. The progression in prodrug designing holds a potential future for ophthalmic drug delivery.
Collapse
|
9
|
Zamboulis A, Nanaki S, Michailidou G, Koumentakou I, Lazaridou M, Ainali NM, Xanthopoulou E, Bikiaris DN. Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments. Polymers (Basel) 2020; 12:E1519. [PMID: 32650536 PMCID: PMC7407599 DOI: 10.3390/polym12071519] [Citation(s) in RCA: 82] [Impact Index Per Article: 20.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2020] [Revised: 07/03/2020] [Accepted: 07/03/2020] [Indexed: 02/06/2023] Open
Abstract
Chitosan (CS) is a hemi-synthetic cationic linear polysaccharide produced by the deacetylation of chitin. CS is non-toxic, highly biocompatible, and biodegradable, and it has a low immunogenicity. Additionally, CS has inherent antibacterial properties and a mucoadhesive character and can disrupt epithelial tight junctions, thus acting as a permeability enhancer. As such, CS and its derivatives are well-suited for the challenging field of ocular drug delivery. In the present review article, we will discuss the properties of CS that contribute to its successful application in ocular delivery before reviewing the latest advances in the use of CS for the development of novel ophthalmic delivery systems. Colloidal nanocarriers (nanoparticles, micelles, liposomes) will be presented, followed by CS gels and lenses and ocular inserts. Finally, instances of CS coatings, aiming at conferring mucoadhesiveness to other matrixes, will be presented.
Collapse
Affiliation(s)
- Alexandra Zamboulis
- Laboratory of Polymer Chemistry & Technology, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; (S.N.); (G.M.); (I.K.); (M.L.); (N.M.A.); (E.X.)
| | | | | | | | | | | | | | - Dimitrios N. Bikiaris
- Laboratory of Polymer Chemistry & Technology, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; (S.N.); (G.M.); (I.K.); (M.L.); (N.M.A.); (E.X.)
| |
Collapse
|
10
|
Dave V, Tak K, Sohgaura A, Gupta A, Sadhu V, Reddy KR. Lipid-polymer hybrid nanoparticles: Synthesis strategies and biomedical applications. J Microbiol Methods 2019; 160:130-142. [DOI: 10.1016/j.mimet.2019.03.017] [Citation(s) in RCA: 88] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2019] [Revised: 03/09/2019] [Accepted: 03/17/2019] [Indexed: 11/28/2022]
|
11
|
Taghe S, Mirzaeei S. Preparation and characterization of novel, mucoadhesive ofloxacin nanoparticles for ocular drug delivery. BRAZ J PHARM SCI 2019. [DOI: 10.1590/s2175-97902019000117105] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Affiliation(s)
- Shiva Taghe
- Kermanshah University of Medical Sciences, Iran; Pharmaceutical Sciences Branch, Iran
| | - Shahla Mirzaeei
- Kermanshah University of Medical Sciences, Iran; Kermanshah University of Medical Sciences, Iran
| |
Collapse
|
12
|
Sharif Makhmal Zadeh B, Niro H, Rahim F, Esfahani G. Ocular Delivery System for Propranolol Hydrochloride Based on Nanostructured Lipid Carrier. Sci Pharm 2018; 86:E16. [PMID: 29677103 PMCID: PMC6027676 DOI: 10.3390/scipharm86020016] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2018] [Revised: 03/31/2018] [Accepted: 04/09/2018] [Indexed: 11/16/2022] Open
Abstract
One drawback of traditional forms of medical ocular dosage is drug dilution by tear; moreover, drugs are rapidly drained away from pre-corneal cavity by tear flow and lacrimo-nasal drainage. Prolonging contact time with different strategies and mucoadhesive vehicles will help to continuously deliver drugs to the eyes. For this study, we prepared and evaluated the effects of a nanostructure lipid carrier (NLC) on propranolol hydrochloride as a hydrophilic drug model for rabbit corneal permeation. Propranolol hydrochloride NLC was prepared using cold homogenization. The lipid was melted, then the drug and surfactant were dispersed and stirred into the melted lipid. This fused lipid phase was scattered in aqueous solution containing the cosurfactant at 4 °C and then homogenized. We evaluated particle size, drug loading, drug release, and NLC permeability through rabbit cornea as well as the formula’s effect on the cornea. Our results show that drug loading efficiency depended on the surfactant/lipid ratio (S/L) and the percentages of liquid lipid and Transcutol (Gattefosse, Saint-Priest, France) (as solubilizer). Drug release data were evaluated with the Higuchi model and a significant correlation was shown between the S/L ratio and the amount of drug released after 4 and 48 h. NLC formulations improved propranolol hydrochloride permeation. We conclude that the effect of the NLC formulations was due to mucoadhesive and film forming properties.
Collapse
Affiliation(s)
- Behzad Sharif Makhmal Zadeh
- Nanotechnology Research Center, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, 6135715794 Ahvaz, Iran.
| | - Hassan Niro
- Department of Pharmaceutics, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, 6135715794 Ahvaz, Iran.
| | - Fakher Rahim
- Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Ciences, 6135715794 Ahvaz, Iran.
| | - Golbarg Esfahani
- Department of Pharmaceutics, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, 6135715794 Ahvaz, Iran.
| |
Collapse
|
13
|
Teixeira GFD, da Costa FN, Campos AR. Corneal antinociceptive effect of (-)-α-bisabolol. PHARMACEUTICAL BIOLOGY 2017; 55:1089-1092. [PMID: 28193100 PMCID: PMC6130487 DOI: 10.1080/13880209.2017.1285944] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
CONTEXT (-)-α-Bisabolol (BISA) is a sesquiterpene alcohol widely used as scent in cosmetic preparations, perfumes, shampoos, toilet soaps and other toiletries with potential for use in the pharmaceutical area. OBJECTIVE To evaluate the corneal antinociceptive efficacy of BISA and to analyze the best solubilizing agent. MATERIALS AND METHODS Acute corneal nociception was induced by the local application of hypertonic saline (5 M NaCl; 20 μL) to the corneal surface of Swiss mice (n = 8/group) 60 min after topical treatment with solutions or ointment containing BISA (50-200 mg/mL). The number of eye wipes performed with the ipsilateral forepaw was counted for a period of 30 s. Control groups (vehicles) were included. RESULTS BISA (50, 100 or 200 mg/mL) solubilized with Tween 80 did not reduce the number of eye wipes. Animals treated with the ointment (BISA 50, 100 or 200 mg/mL; p < 0.001), as well the solution containing propylene glycol (BISA 100 mg/mL; p < 0.05), showed significant reduction in the number of nociceptive behaviours. Solutions containing propylene glycol and isopropyl myristate had no effects. DISCUSSION AND CONCLUSION BISA possess corneal antinociceptive activity. Although the ointment presented antinociceptive effect, it is concluded that BISA when associated with propylene glycol has better potential for corneal nociceptive pain since it is more comfortable to use, leading to greater acceptance by patients.
Collapse
Affiliation(s)
- Gisele Façanha Diógenes Teixeira
- Experimental Biology Centre (Nubex), University of Fortaleza (Unifor), Ceará, Brazil
- School of Medicine, Christus University Centre (Unichristus), Ceará, Brazil
| | | | - Adriana Rolim Campos
- Experimental Biology Centre (Nubex), University of Fortaleza (Unifor), Ceará, Brazil
- CONTACT Adriana Rolim CamposUniversity of Fortaleza, Experimental Biology Centre (Nubex), Av. Washington Soares, 1321, Edson Queiroz, 60.811-905, Fortaleza, Ceará, Brazil
| |
Collapse
|
14
|
Sah AK, Suresh PK. Medical management of glaucoma: focus on ophthalmologic drug delivery systems of timolol maleate. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2016; 45:448-459. [DOI: 10.3109/21691401.2016.1160917] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Abhishek K. Sah
- Faculty of Technology, University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattishgarh, India
| | - Preeti K. Suresh
- Faculty of Technology, University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattishgarh, India
| |
Collapse
|
15
|
Cadinoiu AN, Peptu CA, Fache B, Chailan JF, Popa M. Microparticulated systems based on chitosan and poly(vinyl alcohol) with potential ophthalmic applications. J Microencapsul 2015; 32:381-9. [DOI: 10.3109/02652048.2015.1035682] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
16
|
Abstract
Various strategies for ocular drug delivery are considered; from basic formulation techniques for improving availability of drugs; viscosity enhancers and mucoadhesives aid drug retention and penetration enhancers promote drug transport into the eye. The use of drug-loaded contact lenses and ocular inserts allows drugs to be better placed where they are needed for more direct delivery. Developments in ocular implants gives a means to overcome the physical barriers that traditionally prevented effective treatment. Implant technologies are under development allowing long-term drug delivery from a single procedure, these devices allow posterior chamber diseases to be effectively treated. Future developments could bring artificial corneas to eliminate the need for donor tissue and one-off implantable drug depots lasting the patient's lifetime.
Collapse
|
17
|
Akkurt M, Mohamed SK, Mague JT, Albayati MR, Younes SHH. N'-[(E)-(Furan-2-yl)methyl-idene]-2-[4-(2-methyl-prop-yl)phen-yl]propano-hydrazide. Acta Crystallogr Sect E Struct Rep Online 2014; 70:o356. [PMID: 24765043 PMCID: PMC3998455 DOI: 10.1107/s1600536814003936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Accepted: 02/20/2014] [Indexed: 11/10/2022]
Abstract
In the title mol-ecule, C18H22N2O2, the furan and benzene rings form a dihedral angle of 70.17 (14)°. In the crystal, strong N-H⋯O and weak C-H⋯O hydrogen bonds link the mol-ecules into chains running parallel to [010].
Collapse
Affiliation(s)
- Mehmet Akkurt
- Department of Physics, Faculty of Sciences, Erciyes University, 38039 Kayseri, Turkey
| | - Shaaban K. Mohamed
- Chemistry and Environmental Division, Manchester Metropolitan University, Manchester M1 5GD, England
- Chemistry Department, Faculty of Science, Minia University, 61519 El-Minia, Egypt
| | - Joel T. Mague
- Department of Chemistry, Tulane University, New Orleans, LA 70118, USA
| | - Mustafa R. Albayati
- Kirkuk University, College of Science, Department of Chemistry, Kirkuk, Iraq
| | - Sabry H. H. Younes
- Department of Chemistry, Faculty of Science, Sohag University, 82524 Sohag, Egypt
| |
Collapse
|
18
|
Katiyar S, Pandit J, Mondal RS, Mishra AK, Chuttani K, Aqil M, Ali A, Sultana Y. In situ gelling dorzolamide loaded chitosan nanoparticles for the treatment of glaucoma. Carbohydr Polym 2014; 102:117-24. [DOI: 10.1016/j.carbpol.2013.10.079] [Citation(s) in RCA: 72] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2013] [Revised: 10/22/2013] [Accepted: 10/28/2013] [Indexed: 01/28/2023]
|
19
|
Akkurt M, Mague JT, Mohamed SK, Albayati MR, El-Remaily MAA. 2-(5-Meth-oxy-2-methyl-1H-indol-3-yl)-N'-[(1E,2E)-3-phenyl-prop-2-en-1-yl-idene]acetohydrazide. Acta Crystallogr Sect E Struct Rep Online 2013; 69:o1493. [PMID: 24427110 PMCID: PMC3884474 DOI: 10.1107/s1600536813023805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2013] [Accepted: 08/23/2013] [Indexed: 11/21/2022]
Abstract
The title compound, C21H21N3O2, adopts a J-shaped conformation which appears to be at least partially directed by a weak intra-molecular C-H⋯N hydrogen bond. In the crystal, mol-ecules are linked by N-H⋯O hydrogen bonds into R 2 (2)(8) and R 2 (2)(14) cyclic dimers, which form a chain running parallel to the b axis.
Collapse
Affiliation(s)
- Mehmet Akkurt
- Department of Physics, Faculty of Sciences, Erciyes University, 38039 Kayseri, Turkey
| | - Joel T. Mague
- Department of Chemistry, Tulane University, New Orleans, LA 70118, USA
| | - Shaaban K. Mohamed
- Chemistry and Environmental Division, Manchester Metropolitan University, Manchester M1 5GD, England
- Chemistry Department, Faculty of Science, Minia University, 61519 El-Minia, Egypt
| | - Mustafa R. Albayati
- Kirkuk University, College of Science, Department of Chemistry, Kirkuk, Iraq
| | - Mahmoud A. A. El-Remaily
- Department of Organic Chemistry, Faculty of Science, Institute of Biotechnology, Granada University, Granada E-18071, Spain
- Department of Chemistry, Sohag University, 82524 Sohag, Egypt
| |
Collapse
|
20
|
Singh J, Chhabra G, Pathak K. Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulatein situgel for sustained ocular delivery:in vitro. ex vivoevaluation and pharmacodynamic study. Drug Dev Ind Pharm 2013; 40:1223-32. [DOI: 10.3109/03639045.2013.814061] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|